FBLG (FibroBiologics, Inc.) Company Net Income

FBLG (FibroBiologics, Inc.) - company brandmark

FibroBiologics, Inc. (FBLG) bottom-line profit dynamics correlate with cell product trial results and R&D expense control. The -0.02 mark serves as a key metric on this chart. Operational efficiency is based on the competencies of specialized experts, while revenue growth potential relies on a unique tissue regeneration platform that enables the company to maintain pricing power in the medical sector.

FBLG: FibroBiologics Inc. Company Net Income 02/21/2024 - 10/30/2026

Financial and market metric breakdowns for fibrobiologics.com (FBLG)

- price and consensus price forecast:
Stock Quotes FibroBiologics|FBLG - Analyst Consensus Forecast
- business market valuation indicators:
Market Value FibroBiologics, Inc.|FBLG - Total Company Value
- balance sheet equity data:
Net Assets per Single Share FibroBiologics|FBLG - Company Book Value|Market Value to Book Value Ratio fibrobiologics.com|FBLG - Aggregate Company Assets
- debt and liquidity details:
Total Debt to Capital Coefficient FibroBiologics, Inc.|FBLG - Long-Term Debt to Capital|Current Liabilities to Equity FibroBiologics|FBLG - Company Aggregate Debts|Debts to Net Assets FibroBiologics, Inc.|FBLG - Company Long-Term Debts|Company Short-Term Debt FibroBiologics|Intermediate Coverage Ratio fibrobiologics.com
- earnings and valuation multiples information:
FBLG - Company Net Income
Fundamental valuation:FBLG - FibroBiologics Corp
Mass-produced product of fibrobiologics.com

For FibroBiologics, Inc., the company's net financial flow on the GURU.Markets platform reflects the actual cash return from the commercialization of regenerative technologies. This indicator measures actual equity value through the remaining cash balance, allowing for an assessment of capital management efficiency during the clinical trial period of fibroblast therapy and the monetization of the patent portfolio, separating the business's fundamental stability from speculative market expectations.

Direct competitors

Net Income Mesoblast Pharma|LCTX (Lineage Cell Therapeutics) - Net Profit|Company Net Income surrozen.com SRZN|Company Net Income Cryo-Cell International (CCEL)|Company Net Income LGVN (Longeveron Inc)|Company Net Income BioRestorative Therapies, Inc. BRTX|Creative Medical Technology Holdings, Inc. - Company Net Income